Sun Pharmaceutical Industries Toekomstige groei

Future criteriumcontroles 1/6

Sun Pharmaceutical Industries zal naar verwachting groeien in winst en omzet met respectievelijk 12.6% en 9.9% per jaar. De winst per aandeel zal naar verwachting groeien met 12.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17% zijn.

Belangrijke informatie

12.6%

Groei van de winst

12.5%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.2%
Inkomstengroei	9.9%
Toekomstig rendement op eigen vermogen	17.0%
Dekking van analisten	Good
Laatst bijgewerkt	31 Oct 2024

Recente toekomstige groei-updates

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25

Recent updates

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Oct 21

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Aug 24

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

May 22

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Dec 18

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Oct 04

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Jul 03

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Jun 15

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Mar 14

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50

Feb 03

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well

Dec 09

Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?

Oct 13

These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely

Sep 04

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Aug 05

Winst- en omzetgroeiprognoses

NSEI:SUNPHARMA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	642,585	149,612	121,192	156,146	31
3/31/2026	587,125	132,881	106,693	135,774	36
3/31/2025	529,393	115,321	96,516	117,323	36
9/30/2024	503,077	110,541	129,355	151,468	N/A
6/30/2024	492,088	103,895	N/A	N/A	N/A
3/31/2024	484,969	95,764	99,332	121,350	N/A
12/31/2023	474,446	89,063	N/A	N/A	N/A
9/30/2023	463,049	85,485	96,498	116,171	N/A
6/30/2023	450,648	84,352	N/A	N/A	N/A
3/31/2023	438,857	84,736	28,738	49,593	N/A
12/31/2022	424,018	42,119	N/A	N/A	N/A
9/30/2022	410,239	41,047	24,284	40,183	N/A
6/30/2022	396,975	38,894	N/A	N/A	N/A
3/31/2022	386,545	32,727	74,895	89,845	N/A
12/31/2021	377,307	64,441	N/A	N/A	N/A
9/30/2021	367,044	62,378	67,751	82,511	N/A
6/30/2021	356,316	60,036	N/A	N/A	N/A
3/31/2021	334,981	29,038	50,002	61,704	N/A
12/31/2020	331,601	24,095	N/A	N/A	N/A
9/30/2020	324,782	14,706	33,332	47,270	N/A
6/30/2020	320,484	7,219	N/A	N/A	N/A
3/31/2020	328,375	37,649	50,128	65,548	N/A
12/31/2019	318,165	40,010	N/A	N/A	N/A
9/30/2019	314,018	43,293	26,411	43,521	N/A
6/30/2019	302,161	29,956	N/A	N/A	N/A
3/31/2019	290,659	26,654	-10,164	21,965	N/A
12/31/2018	288,052	34,379	N/A	N/A	N/A
9/30/2018	277,182	24,380	N/A	N/A	N/A
6/30/2018	275,048	35,690	N/A	N/A	N/A
3/31/2018	264,155	20,957	N/A	39,072	N/A
12/31/2017	263,811	20,763	N/A	N/A	N/A
9/30/2017	276,530	31,827	N/A	N/A	N/A
6/30/2017	295,310	45,057	N/A	N/A	N/A
3/31/2017	313,081	69,644	N/A	70,822	N/A
12/31/2016	319,185	73,270	N/A	N/A	N/A
9/30/2016	311,431	74,000	N/A	N/A	N/A
6/30/2016	297,512	61,937	N/A	N/A	N/A
3/31/2016	281,086	45,457	N/A	66,859	N/A
12/31/2015	266,281	38,915	N/A	N/A	N/A
9/30/2015	264,670	28,702	N/A	N/A	N/A
6/30/2015	276,422	38,150	N/A	N/A	N/A
3/31/2015	273,920	45,394	N/A	56,157	N/A
12/31/2014	170,765	59,141	N/A	N/A	N/A
9/30/2014	170,835	60,202	N/A	N/A	N/A
6/30/2014	165,250	58,100	N/A	N/A	N/A
3/31/2014	160,804	31,415	N/A	39,592	N/A
12/31/2013	150,933	26,104	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei SUNPHARMA ( 12.6% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van SUNPHARMA ( 12.6% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 18.1% per jaar).

Hoge groeiwinsten: De winst van SUNPHARMA zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van SUNPHARMA ( 9.9% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 10.2% per jaar).

Hoge groei-inkomsten: De omzet van SUNPHARMA ( 9.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen SUNPHARMA zal naar verwachting over 3 jaar laag zijn ( 17 %).

Sun Pharmaceutical Industries Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target increased by 8.8% to ₹2,023

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Price target increased by 7.0% to ₹1,749

Price target increased by 7.2% to ₹1,746

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Recent updates

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target increased by 8.8% to ₹2,023

Second quarter 2025 earnings: EPS exceeds analyst expectations

Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference

Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Sun Pharma Introduces Novel Treatment, Tedizolid Phosphate in India for Acute Bacterial Skin and Skin Structure Infection

Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2023-2024

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Price target increased by 7.0% to ₹1,749

Price target increased by 7.2% to ₹1,746

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Sun Pharmaceutical Industries Limited Receives Approval from U.S. Food and Drug Administration for LEQSELVITM (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata

Sun Pharmaceutical Industries Limited to Report Q1, 2025 Results on Aug 01, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₹5.00 per share

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately

Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults

Sun Pharmaceutical Industries Limited, Annual General Meeting, Aug 05, 2024

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million.

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

Sun Pharmaceutical Industries Limited to Report Q4, 2024 Results on May 22, 2024

Sun Pharmaceutical Industries Limited Announces Executive Changes

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million.

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to ₹8.50

Price target increased by 9.3% to ₹1,453

Third quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024

Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Sun Pharmaceutical Industries Limited Announces Management Changes

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023

Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million.

Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million.

Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Price target increased by 7.0% to ₹1,229

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV®

Upcoming dividend of ₹4.00 per share at 1.0% yield

High number of new directors

Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023

Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023

Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne

Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions

We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Sun Pharmaceutical Industries Limited Announces Board Appointments

Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023

Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update

Whole Time Director recently sold ₹3.9m worth of stock

Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion.